Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Strike Pharma AB has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is currently confined to 1 distinct examiner and 1 distinct art unit. This singular focus suggests that the company's intellectual property is currently centered on a specific pharmaceutical or biotechnological innovation that fits within a single technical classification at the patent office.
The busiest examiner, ZEMAN, ROBERT A, is assigned 1 busiest examiner pending office action. This action is the only one currently pending for the company, making the examiner's individual perspective the most influential factor in the portfolio's immediate future. The presence of only 1 distinct art unit means that the company does not have to navigate the differing procedural expectations of multiple units.
Practitioners should focus their efforts on the 1 pending office action and the specific examination habits of ZEMAN, ROBERT A, to ensure a smooth prosecution process. Investigating the examiner's typical approach to Biotechnology & Pharmaceuticals claims can provide a strategic advantage. Resolving the 1 pending office action with this 1 examiner is the primary objective for the company's current patent strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17292974 | BI-SPECIFIC CONJUGATES | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17292974 | BI-SPECIFIC CONJUGATES | ZEMAN, ROBERT A | 1645 | DP | Non-Final OA | — | Pending | May 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStrike Pharma AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Zeman has the most, with 1 of Strike Pharma AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
